Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425644 · ClinicalTrials.gov registry record · Phase 3
Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
A Phase 3 study of Multiple Sclerosis, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,133
- Enrollment target
- 20
- Study locations
NCT02425644: Completed Phase 3 study of Multiple Sclerosis, sponsored by Actelion.
NCT02425644 is a Phase 3 study of Multiple Sclerosis that has completed, run by Actelion. The registered enrollment target is 1,133 participants, above the 581-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (95% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02425644, a Phase 3 study of Multiple Sclerosis, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,133 participants
- Enrollment target
- 20
- Study locations
Study Summary
International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis
Primary Outcome
Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its
Conditions Studied
Interventions
- DRUG ponesimod
- DRUG teriflunomide
Study Locations (20)
Other
- Investigator Site 3605 - Grodno
- Investigator Site 3603 - Minsk
- Investigator Site 3602 - Minsk
- Investigator Site 3606 - Vitebsk
- Investigator Site 3604 - Vitebsk
- Investigator Site 9104 - Sarajevo
- Investigator Site 2709 - Plovdiv
- Investigator Site 2711 - Sofia
- Investigator Site 2702 - Sofia
- Investigator Site 2707 - Sofia
California
- Investigator Site 8045 - Carlsbad
- Investigator Site 8311 - Pomona
Florida
- Investigator Site 8065 - Ormond Beach
- Investigator Site 8018 - Tampa
Colorado
- Investigator Site 8036 - Denver
Indiana
- Investigator Site 8013 - Indianapolis
North Carolina
- Investigator Site 8040 - Raleigh
Ohio
- Investigator Site 8006 - Columbus
Tennessee
- Investigator Site 8015 - Franklin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,133 participants |
| Start Date | 2015-06-04 |
| Est. Completion | 2019-05-16 |
| Phase | Phase 3 |
What the finished NCT02425644 record still lists
NCT02425644 is an interventional study that assigns participants to a tested intervention. Its 1,133 participants enrollment target places it among the larger protocols in the corpus, above the 581-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (95% higher).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which ponesimod is the first listed.
NCT02425644 names 20 study sites across 9 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02425644 about?
NCT02425644 is a clinical study titled "Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis". International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis
What is the current status of trial NCT02425644?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,133 participants. The study started on 2015-06-04. Estimated completion is 2019-05-16.
What conditions does trial NCT02425644 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT02425644?
The interventions under investigation include: ponesimod (DRUG), teriflunomide (DRUG).
Who is sponsoring clinical trial NCT02425644?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02425644 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Indiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02425644's enrollment target sits among peer trials
1,133 22nd of 315 higher than 294 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06445062 · 1,130 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
- NCT06746129 · 1,126 participants · Phase 3
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI